

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



Data Sheet (Cat.No.T6045)



Torin 1

Chemical Properties

CAS No.: 1222998-36-8

Formula: C35H28F3N5O2


Molecular Weight: 607.62

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

selectivity for mTOR than PI3K.

DNA-PK,PI3K,mTOR,Autophagy



Biological Description

Description

Targets(IC50)

proliferation was detected by CellTiterGlo viability assay. RESULTS: 250 nm Torin1 completely inhibited cell proliferation. [1] METHODS: The human endocrine cell line BON was treated with Torin for 3-24 h, and the expression level of target proteins was measured line RESULTS: Torin1 increased NT secretion in a dose-dependent manner increased 3-24 h after Torin1 treatment. Torin1 treatment decreased t phosphorylation of Akt (S473), and the phosphorylation of p70S6K (T3 (T37/46) was also inhibited. [2] In vivo METHODS: To assay anti-tumor activity in vivo, Torin 1 (20 mg/kg, 20% pyrrolidone, 40% PEG400 and 40% water) was administered intraperit nude mice bearing human glioblastoma U87MG once daily for ten day RESULTS: Continuous administration of the drug for ten days resulted 99% inhibition of tumor growth. Tumor growth continued after discondrug, suggesting that Torin 1 treatment is primarily cytostatic and that of tumor cells remain viable during treatment. [3] Kinase Assay MTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTO lines that stably express N-terminally FLAG-tagged Raptor are generated. Bot purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyropl sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. °C for 30 min, and the insoluble fraction is removed by microcentrifug rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclone agarose for 1 h and then washed three times with lysis buffer and one containing a final concentration of 0.5 M NaCl. Purified mTORC1 is elu μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase as performed for 20 min at 30 °C in a final volume of 20 μL consisting of the process of the purified mTORC1 is eluand stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase as performed for 20 min at 30 °C in a final volume of 20 μL consisting of the process of the purified mTORC1 is eluand stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kina	Divit i Kiji i Bikijimi dikiji katopilagy
pyrrolidone, 40% PEG400 and 40% water) was administered intraperit nude mice bearing human glioblastoma U87MG once daily for ten day RESULTS: Continuous administration of the drug for ten days resulted 99% inhibition of tumor growth. Tumor growth continued after discon drug, suggesting that Torin 1 treatment is primarily cytostatic and that of tumor cells remain viable during treatment. [3] Kinase Assay MTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTO lines that stably express N-terminally FLAG-tagged Raptor are general stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar stably express N-terminally FLAG-tagged Protor-1 are generated. Bot purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyroph sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. °C for 30 min, and the insoluble fraction is removed by microcentrifug rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclone agarose for 1 h and then washed three times with lysis buffer and oncontaining a final concentration of 0.5 M NaCl. Purified mTORC1 is elupg/mL 3xFLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase as performed for 20 min at 30 °C in a final volume of 20 µL consisting of the store of the substrates and stored at -80 °C. Substrates S6K1 and Akt1 are purified.	RESULTS: 250 nm Torin1 completely inhibited cell proliferation. [1] METHODS: The human endocrine cell line BON was treated with Torin 1 (62.5-150 μM) for 3-24 h, and the expression level of target proteins was measured by Western Blot. RESULTS: Torin1 increased NT secretion in a dose-dependent manner; NT secretion was increased 3-24 h after Torin1 treatment. Torin1 treatment decreased the phosphorylation of Akt (S473), and the phosphorylation of p70S6K (T389) and 4E-BP1
lines that stably express N-terminally FLAG-tagged Raptor are general stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar stably express N-terminally FLAG-tagged Protor-1 are generated. Bot purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyroph sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. °C for 30 min, and the insoluble fraction is removed by microcentrifug rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal agarose for 1 h and then washed three times with lysis buffer and one containing a final concentration of 0.5 M NaCl. Purified mTORC1 is elumed for 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase as performed for 20 min at 30 °C in a final volume of 20 μL consisting of the store of the substrates should be substrated by the substrate of the substrat	METHODS: To assay anti-tumor activity in vivo, Torin 1 (20 mg/kg, 20% N-mentyl-2-pyrrolidone, 40% PEG400 and 40% water) was administered intraperitoneally to NCR nude mice bearing human glioblastoma U87MG once daily for ten days. RESULTS: Continuous administration of the drug for ten days resulted in greater than 99% inhibition of tumor growth. Tumor growth continued after discontinuation of the drug, suggesting that Torin 1 treatment is primarily cytostatic and that a large number of tumor cells remain viable during treatment. [3]
(25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl2, 500 μm ATP) and 15	mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibodyagarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl2, 500 μm ATP) and 150 ng of inactive

Torin 1 is an effective inhibitor of mTORC1/2 with (IC50: 2 nM/10 nM); has 1000-fold

7.0.	S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μ L of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research	Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 µL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)

Solubility Information

Solubility	DMSO: 1 mg/mL,Sonication is recommended.		
	(< 1 mg/ml refers to the product slightly soluble or insoluble)		

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6458 mL	8.2288 mL	16.4577 mL
5 mM	0.3292 mL	1.6458 mL	3.2915 mL
10 mM	0.1646 mL	0.8229 mL	1.6458 mL
50 mM	0.0329 mL	0.1646 mL	0.3292 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Lu X Y, Shi X J, Hu A, et al. Feeding induces cholesterol biosynthesis via the mTORC1-USP20-HMGCR axis. Nature. 2020, 588(7838): 479-484.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com